<DOC>
	<DOCNO>NCT00729573</DOCNO>
	<brief_summary>The MTN-003 HIV prevention study include use microbicides , substance kill microbe , tenofovir disoproxil fumarate ( TDF ) emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) - oral , FDA-approved , anti-HIV drug . The purpose study determine take daily TDF FTC/TDF part study MTN-003 effect bone mineral density ( BMD ) .</brief_summary>
	<brief_title>Bone Mineral Density Substudy - An Ancillary Study MTN-003</brief_title>
	<detailed_description>The effect tenofovir bone mineral density ( BMD ) yet study potential concern . The purpose study determine change BMD among individual receive TDF FTC/TDF compare placebo . This substudy enroll individual currently participate MTN-003 . The expected duration participation participant approximately 48 month . Study treatment provide MTN-003 . Study treatment provide substudy . Study visit occur every 6 month enrollment . A nutrition assessment , physical activity history , urine blood collection occur visit .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Enrolled MTN003 Randomized oral study product MTN003 within 14 day prior study entry Medical condition know affect bone take medication know affect bone . More information criterion find protocol . Permanently discontinue oral study product MTN003 prior study entry Any condition , opinion investigator , would interfere study Pregnant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Microbicide</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Bone Mineral Density</keyword>
</DOC>